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A group of 456 consecutive patients seen r36 h after the
onset of acute myocardial infarction associated with ST
segment elevation received thrombolytic therapy and were
followed up for 12 months . Intravenous streptokinase was
given to 315 patients and recombinant tissue-type plasmin-
egen activator (rt-PA) to 141 patients. Reinfardion rate
and risk factors for relnfardion were assessed . Manage-
ment after thromholysis was conservative ; revasculariza-
lion procedures were reserved for patients with symptoms
refractory to medical therapy or far those with left main
coronary artery slenosis. Coronary artery surgery or an-
gloplasty was performed in only 3 .7% of patients during
the first 30 days after thrombolysis and in only 8 .6% by
I year. Most patients (79%) underwent coronary arleriog-
raphy.
Twenty-six patients (5.7%) exhibited signs of threatened
reinfarction at I month after thrombolytic therapy as did
43 patients (9.4%) by 1 year. Reiofarction was prevented in
four of these patients by early readministre tion of throm-
The use of thrombolytic therapy to dissolve occlusive coro-
nary artery thrombus has been clearly shown to reduce
mortality from acute myocardial infarction and to limit the
extent of left ventricular damage (1-5). Restoration of coro-
nary artery patency may leave the vessel with a severe
residual stenosis, an unstable endothelial lesion and residual
thrombus
. Angiographic studies (6) showed a high rate of
early reocciusion, which led to the adoption of strategies that
included early angiography and angioplasty (7,8) .
However,
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bolytic therapy. Multivariate analysis of possible risk fac-
tors for reinfarction identified at the time of initial
e&a.c
lion showed current cigarette smoking to be the only
predictive factor (reinfardion occurred in 12 .5% of smok-
ers versus 6 .3% of nonsmokers, p = 0.04) . A second
analysis of risk factors identified 3 weeks after initial
infarction, including the severity of residual stenesis at
coronary arteriography and exercise test variables, again
showed continued cigarette smoking to be the only factor
predictive of reinfarcdon . Twenty percent of patients who
continued to smoke developed reinfarction compared with
5.1% of those who stopped (p < 0.01).
Conservative management after thrombolysis with
streptokinese or rt-PA results is a reinfarction rate of 8.6%
at I year . Cigarette smoking predisposes patients to rein.
farction
; cessation of smoking reduces the risk of reinfarc-
uon. The Impact of threatened reinfarction can be limited
by prompt readministratioo of thrombolytic therapy .
(J Am Coll Cordial 1960;16 :340-8)
four studies (9-12) of angioplasty after thrombolytic therapy
showed no benefit in terms of reduction of reocciusion
. The
Thrombolysis in Myocardial Infarction (TIMI) Phase 11 trial
(12) supported a strategy of watchful waiting with angio-
plasty or bypass surgery reserved for patients who had
recurrent ischemia or ischemia provoked during a predis-
charge exercise test. However, in that study 25 .3% of
patients managed with a conservative strategy underwent
angioplasty or surgery within 42 days after infarction .
Reocclusion of a coronary artery may result in reinfarc-
tion or, alternatively, become manifest as recurrent angina
or be totally asymptomatic
(6). Although silent reocciusion
may have a number of adverse effects (13,14), clinical
reinfarclion is likely to have a more immediate impact on
mortality and left ventricular function than is silent reocclu-
510n.
The present study assessed the 12 month incidence of
0735-1097/90/x3.50
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reinfarction after thrombolytic therapy with streptokinase or
recombinant tissue-type plasminogen activator (rt-PA) and
conservative treatment in which only patients with signifi-
cant left main coronary artery disease or Canadian Cardio-
vascular Society grade Ill or IV angina (151 despite medical
therapy underwent angioplasty or bypass surgery. By 42
days only 4 .2% of patients had had surgery or angioplasty .
We also examined the risk factors that might predispose
patients in this group to reinfarction as well as the impact of
reinfarction on left ventricular function
.
Study patients. The study group comprised 456 consecu-
tively hospitalized patients who received intravenous throm-
bolytic therapy <_6 h after the onset of ischemic chest pain
.
One hundred four patients were randomized to receive
streptokinase therapy in a double-blind trial (3) of streptoki-
na, e versus placebo, whereas 270 patients were randomized
to receive either streptokinase (n = 135) or rt-PA In = 135)
in a second trial (16) comparing the effect of the two agents
on subsequent left ventricular function . An additional 82
patients were treated electively with either streptokinase
(n = 76) or rt-PA (n = 6) .
Patients entered into the randomized trials were admitted
to one of the four coronary care units in Auckland . whereas
all patients in the elective thrombolytis group were admitted
to the Green Lane Hospital coronary care unit . In the first
trial, patients were enrolled <_4 h after the onset of chest pain
and in the second trial <_3 It after the onset of pain . Entry
criteria for both trials included 30 min of chest pain associ-
ated with >_1 mm ST segment elevation on the electrocar-
diogram (ECG) in precordial leads V
4
to V6 or the limb leads,
or m2 mm ST segment elevation in leads V I to V, . These
changes were required is two or more leads and patients
with bundle branch block were excluded .
Exclusion criteria were a history of stroke or bleeding
disorder, confirmed peptic ulcer or genitourinary bleeding
within the preceding 6 months, hypertension (systolic pres-
sure >200 mm Hg not readily lowered with short-term
antihypertensive therapy), current warfarin therapy and
surgery or trauma within the preceding 2 weeks . Patients
with cardiogenic shock and patients with brief cardiopulmo-
nary resuscitation (<10 min) were not excluded. The trials
were approved by the ethics committees of the participating
hospitals.
The patients treated electively were ineligible for the
randomized trials because they were >70 years of age (n =
28), had previous myocardial infarction (n = 37) or had pain
lasting >3 but <6 h (n = 28) . Some patients were ineligible
for more than one reason .
Thrombelytic and adjtarctive therapy. Of the 456 pa-
tients, 315 received 1 .5 x 106 U intravenous streptokinase
administered over 30 min and 141 received 100 mg rt-PA
administered as a 10 mg bolus followed by 50 mg infused
over I h and 40 mg over the next 2 h. All patients without a
history of aspirin intolerance received aspirin (dosage range
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50 to 300 mg/day) on admission and for a21 days
. In
addition . 380 patients (88%) received 200 mg dipyridamole
twice daily for the same period . Most patients were subse-
quently randomized to receive aspirin and dipyridamol ~ or
placebo in an ongoing trial that remains blinded . Heparin
was administered by intravenous infusion for 48 h at an
initial dose of 1,000 U/h immediately after completion of
thrombolytic therapy, with subsequent dose adjustment to
maintain an activated partial thromboplastin time of 90 to
110 s. Oral beta-adrenergic blocking therapy was initiated in
patients without contraindications s3 days after hospital
admission. At hospital discharge, 54% of patients were
receiving a beta-blocker
.
Neither coronary angioplasty nor coronary artery bypass
grafting was performed solely on the basis of anatomic
findings, with the exception of surgery for left main coronary
stenosis
. Severe angina (grade Ill or IV) (IS) that was
refractory to medical therapy was treated with either angio-
plasty or bypass surgery
. Medical therapy in such cases
generally included beta-blockade, a calcium antagonist and
nitrates.
Angiographic analysis. Coronary arteriography and left
ventricutography were performed 3 weeks after initial in-
farction in all consenting patients enrolled in the trials of
thrombolytic therapy
. Subsequent cardiac ca
•4
eterization in
these patients and in patients receiving elective thrombo'ysis
was determined by clinical indications such as recur .ent
angina or an abnormal exercise stress test . A total of 331
patients underwent catheterization 28 = 11 days after the
index infarction and an additional 30 patients were studied at
a median of 40 (range 0 to 505) days after reinfarction
.
Patency of the infarct-related artery was classified ac-
cording to the criteria of the TIMI trial (17)
.
Coronary artery
stenoses were measured by experienced cardiac radiologists
and graded according to cross-sectional area loss . Stenoses
were assessed in two orthogonal views
. The overall severity
of coronary disease was assessed by a scoring system that
incorporated both the degree of coronary artery stenoses and
the amount of myocardium supplied distal to each lesion
(18). Left ventriculography was performed simultaneously in
the right anterior oblique and cranially angulated left anterior
oblique projections. Ventricular volumes, ejection fraction
and regional wall motion abnormality scores were calculated
as previously described (3,16 .19). Regional wall motion was
graded as follows: 0 = normal, I = hypokinetic, 2 =
akinetic . 3 = dyskinetic . The biplane images were divided
into five regions in each projection and the 10 resultant
scores summed to produce the index reported.
Exercise testing. Two hundred ninety-five patients under-
went symptom-limited treadmill exercise testing 3 weeks
after the index infarction . A modified Bruce protocol was
used
. Twelve ECG leads were monitored during exercise.
Identification of rinfardion. Patients were reviewed at a
special clinic every 3 to 6 months
. An ECG was obtained at
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each clinic visit and at the time of cardiac catheterization .
Information for patients not followed up at Green Lane
Hospital was obtained from their general practitioners . Com-
plete 12 month follow-up evaluation was available for 453
patients (99 .3%) .
For the purpose of
risk factor analysis, three groups of
patients Ivere defined .
The first comprised patients with
ischemic pain a30 min in duration accompanied by elevation
in serum creatine kinase levels above the upper limit of the
reference range for our laberatory (300 (Ulliter), with or
without progressive ECG changes
. A second group com-
prised patients with histologic evidence of reinfarction at
autopsy
. The final group comprised patients with signs of
reinfaretion characterized by ischemic pain 030 min in
duration with significant ST segment elevation . These pa-
tients were treated with readministration of thrombolytic
therapy and had no evolution of ECG changes orelevation of
cardiac enzyme levels. It is likely that reinfaretion was
prevented in these patients by early dissolution of occlusive
thrombus and they have therefore been included in the
analysis of risk factors for reinfarction .
Statistical analysis . Results for continuous variables are
expressed as mean values ± SD and differences between
means are compared by one-way analysis of variance
. All p
values reported are two tailed . Where data distribution did
not approximate normal distribution, the median value and
range are reported and differences between groups examined
by the Mann-Whitney U test. Categoric variables are com-
pared by the chi-square test with Yates' correction for
continuity in 2 x 2 tables ; p values of <0 .05 are regarded as
significant .
Two separate analyses ofpotential risk factors for rein-
farction were performed: the first examined factors identified
at the time of the index infarction that might predispose the
patient to reinfaretion during the entire study period and the
second examined factors defined 3 weeks after the index
jrforefion that might predict reinfartion . The following
categoric variables were examined at the time of the index
infarction: cigarette smoking, site of infarct, gender, pres-
ence of Q waves, history of angina, diabetes or hypertension
and thrombolytic agent administered. Age was examined as
a continuous variable
. The analysis of factors identified at 3
weeks included all those identified at the time of infarction as
well as the following categoric variables : beta-bloeker ther-
apy, patency of infarct artery, angina at exercise testing and
ST segment depression during exercise . Additional continu-
ous variables in the 3 week analysis were stenosis of the
patent infarct artery, coronary artery score (10), exercise
duration and peak heart rate and systolic blood pressure
during the exercise test. Results presented in the tables are
from univariate comparison of each variable between the
reinfarction and nonreinfarction groups. Multiple stepwise
logistic regression analysis incorporating all variables was
also performed on both data sets .
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Figure 1. Actuarial incidence of reinfarction (n = 43).
Results
Reinfaretlon
(Fig
. 1). In 36 patients reinfaretion was
diagnosed on the basis of prolonged ischemic chest pain at
rest with subsequent elevation of cardiac enzyme levels and
with or without progressive ECG changes. Reinfarction was
diagnosed at autopsy in three patients . Four patients who
underwent readministration of thrombolysis for presumed
thrombotic coronary occlusion (ischemic pain lasting >30
min with ST segment elevation) but who did not subse-
quently develop increased serum creatine kinase levels were
included in the risk factor analysis .
Reinfarction occurred early (s30 days after the index
infarction) in 26 patients (5 .7%) and between I and 12
months after infarction in 17 patients (3 .7%a) . The actuarial
incidence of reinfaretion is displayed in Figure 1 . Reinfare-
tion occurred in the same coronary artery distribution as t1 :e
index infarction in 37 patients and in a different coronary
artery territory in 6. Reinfaretion occurred significantly late;
among the latter patients, after a median of 153 days (range
19 to 296) versus I I days ;range I to 211) (p = 0.003) .
Mortality (Fig. 2). During the 1 year follow-up period, 41
patients died; 34 died after the index infarction and 7 after
reinfarction
. Most deaths (63%) occurred within 30 days of
the index infarction. The actuarial and infarct-free survival
rates are shown in Figure 2. Thirty-five deaths were cardiac
related: 13 patients died suddenly . 16 died of cardiogenic
shock or severe heart failure, 4 of documented cardiac
rupture and 2 after cardiac surgery . Autopsy was performed
in 5 of the 13 patients who died suddenly. None of the other
eight patients who died suddenly were known to have had
chest pain before their collapse, but it is possible that this
group may have included some with undetected reinfarction .
Three patients died of a cerebrovascular accident, two of
JACC Vol. 16. No . 2
August 1990?3Q-s
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Figure 2 . Actuarial and infarct-free survival rates (4). The upper
curve indicates mortality and the lower curve reinfarction . The
percent of patients below the lower curve represents those alive and
free of infarction .
intracerebral bleeding soon after H-PA therapy and one after
a presumed embolic stroke from left ventricular mural
thrombus 6 days after streptokinase therapy . Two patients
died of pneumonia unrelated to the index infarction and one
died of chronic renal failure . The 12 month cardiovascular
mortality rate was 8.3%.
Variables predictive
of reinfarelion Table 2 shows the
results of univariate analysis of a number
of
potential risk
factors for reinfarction, defined at the time o'index infarc-
tion. The only baseline variable associated with subsequent
reinfarction was cigarette smoking at entry to the study
.
Reinfarction within
12
months occurred in
12
.5% of smokers
in comparison with 6.3% of nonsmokers (p = 0.044 . Multi-
variate analysis confirmed that cigarette smoking was the
only factor predictive of reinfarction (p = 0.04) . Site of
infarction, presence or absence of Q waves, thrombolytic
RIVERS Er AL .
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Table 2. Potential Risk Factors for Reinfarction (defined at time
of index infarction) in 456 Patients
agent administered and history
of
previous angina, hyper-
tension or diabetes were not predictive
of
reinfarction
. There
was no significant difference in the age or gender distribution
of patients with subsequent reinfarction .
Table 3 summarizes possible proRnaslic factors for sub-
sequent rinfarclion defined after clinical review, cardiac
Table 3. Potential Risk Factors for Reinfarction (defined 3 weeks
after index infarction) in 407 Patients
exercise
Subsequent
Reinfarction
In = 19)
No Subsequent
Reinfarction
(n = 388)
P
Value
Con)inued smoking 7137%) 28 f8%) <0.001
Inferior infarction 13168%) 212(55%) 035
Non'Q w
infarction 3 )161A) 93124%) 0.59
Female gender 3 (16%) 90(23%) 0.64
Mean age lye) 58 x 10 57 t 10 0.78
t)Iahele, 115%) 38(10%) 0.80
Previous angiw 306%) 77(20%) 0.89
Hypenen.ion 4(21%) %(25%) 0.93
rbPA therapy 6022%) 120131%) 1.00
Sneplula-, therapy 13(69%) 268169%) 1.00
Bela-bfmker therapy 907%) 175(45%) 1 .00
Cathdcn,ation data In = I61 In = 312)
Ptens infarct artery 141889) 238(7656) 0 .46
Mean 9 sleaosis of patent 84.3 ± 11 .7% 83.7 ± 17 .5% 0
.90
infarct anery
Mean roe eary anery 8.0'2.5
8.1+_2 .8 0 .93
core tree text)
Exercise err data (n=16) (n=2791
Mean exercise duration 11 .2 3.2
II .0 t 3 .6
0.81
Inn .)
Anot . during lest 116%) 45(1691 0 .49
Mean peak bean rate 131 z 23 127 ± 24 0.59
)hearsimin)
Mean peak systolic blood 168 t 36 158 2 28 0.15
Fuel- Onun H91
-_ I mm ST segment 3 (19%1
9705%)
0 .30
depression dunes
Reinfarction
In = 431
No Reinfaretion
(n = 4131
P
Value
Smoking 29167%) 203(50%) 0.04
Inferior infarclbn 28(65%1 221(54`,x) 0
.20
Female gender 6(14%) 99124%) 0
.20
NonQ wave
infarction
6119741 97(23%) 0 .59
Nn
is,-- -en
.
36 (849.1 329 (88%) 6.66
Oiaberes 3(77,1 43 1109) 0.66
Mean age (yrl 58 t 9 57 t 10
0
.68
H PA therapy 14133%)
127(31%)
0
.94
Sireptok.nasetherapy
29(67%) 286(69%) 0.94
Hypenensea
10(239) 103125%) 095
Tablet
. Entry Characteristics of 456 Patient%
Nn .
Mean age lye) 57 - 10
Male gender 151 mil
Thrombolnric agent
Streptokinase 115 (6 9A)
n-PA 141 111^n 1
Amertor infarction 2-W 145^91
Smoking 2124517)
Angina (>1 months before admission) 90)209)
Diabetes meliims 46()07)
Hypertension
113 (251)
Previous myocardial infarction 65
)149)
Non-Q waue infarction (051219)
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catheterization and exercise testing at 3 weeks after the
index infarction . Cigarette smoking again emerged as the
only significant prognostic factor . Of the 35 patients (8 .6%)
who were still smoking at 21 days,
7 (20%) subsequently
exhibited reinfarction compared with 12 (3 .4%) of the 354
nonsmokers (p < 0.001) . When the patients smoking at the
time of the index infarction were considered separately, the
incidence of subsequent reinfarction for the 35 patients still
smoking at 21 days was 20% compared with a 5 .1% inci-
dence rate for the 156 patients who had stopped (p < 0 .01).
No exercise test variable evaluated was predictive of
subsequent reinfarction . The mean severity of the residual
stenosis of the infarct-related coronary artery in patients
with subsequent late reinfarction was similar to that in
patients who did not exhibit reinfarction, and patients with
more severe residual lesions were not more prone to rein-
farction . The 12 month reinfarction
rate in patients with
<75% stenosis (<50% diameter) was 2 .6%, in those with
75% to 90% stenosis (50% to 70% diameter) it was 10.2% and
in those with 9Dulo to 99% stenosis (70% to 90% diameter) it
was 5.3% . None of the 24 patients with 99% stenosis (>90
diameter) developed clinical reinfarction (p = 0 .22).
Patients with subsequent reinfarction had coronary dis-
ease similar in severity to that of patients who did not have
reinfarction,
as reflected by the coronary score. Two (4 .4%)
of 45 patients with a coronary score <5, 11 (5 .6%) of 195
patients with a score between 5 and 10 and 3 (3
.4%) of 88
patients with a score >10 had subsequent reinfarction (p =
0.7). A score of <5 approximates single vessel disease and a
score of S to 10 double vessel disease and of >10 triple vessel
disease .
Readministration of thrombolytic therapy. Thirteen of the
43 patients with threatened reinfarction received further
thrombolytic therapy, 8 with streptokinase and 5 with rt-PA .
Administration of streptokinase was avoided between 5 days
and 3 months after prior streptokinase therapy
. Four pa-
tients who received thrombolytic therapy (two with strep-
tokinase and two with rt-PA) for recurrent prolonged pain
with ST segment elevation did not subsequently evolve ECG
patterns or cardiac enzyme levels indicating infarction . One
patient died of an intracerebellar hemorrhage 21 h after
receiving rt-PA for signs of reinfarction 7 days after strep-
tokinase therapy . Of the five patients who received strep .
tokinase twice, two developed a mild allergic reaction .
Cardiac catheterigatton and left ventricular function
.
Table 4 compares the cardiac catheterization findings after
the first infarction with findings after reinfarction . Left
ventricular volume and ejection fraction were similar in
patients with and without reinfarction, although the regional
wall motion score was worse after reinfarction . The infarct-
related coronary artery was more likely to be occluded after
reinfarction (47% versus 24%, p = 0.01).
We also compared cardiac catheterization data for the 16
patients for whom data were available before the reinfarction
Table 4 . Cardiac Catheterization Data in 354 Patients
JACC Vat. 16, No
.2
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'TIMI grade 2 or 3. Data represent mean values z SD . LVEDP = left
ventricular end-diastolic
pressure
.
with those for the 30 for whom data were available after
reinfarction (Table 5) . End-diastolic volume was signifi-
cantly greater in patients after reinfarction, and a trend
toward increased end-systolic volume was also noted .
Figure 3 illustrates the changes in left ventricular volume
and ejection fraction in the seven patients who underwent
study both before and after reinfarction . Ventricular vol-
umes increased in all these patients (end-systolic volume
31 ± 6 to 64 ± 37 ml, p = 0 .05 ; end-diastolic volume 102 ±
25 to 161 ± 55 ml, p = 0.008), but ejection fraction did not
change .
Cardiac enzymes. The peak creatine kinase level after the
initial infarction in patients with subsequent reinfarction was
2,015 ± 1,558 Miter compared with 2,416 ± 1,939 Miter
in the patients who did not develop reinfarction (p = 0 .20).
Peak creatine kinase level after reinfarction was lower than
after initial infarction at 888 *_ 827 Miter (p < 0.001) or
978 ± 828 Miter (p < 0 .001) if the four patients with no
increase in enzyme level are excluded
. Excluding those
patients with no increased s
e
zyme level, peak creative
kinase in patients given thrombolytic therapy for reinfarction
was 617 ± 202 IUlliter compared with 1,102 ± 925 Miter
for those not given thrombolytic therapy (p = 0.13) .
Table 5. Cardiac Catheterization Data for 39 Patients
With Reinfarction
Data represent mean values ± SD .
After Index
Infarction
and Before
	
After
Reinfanction Reinmrction
P
In
= 16) (n = 30) Vulue
Endmystolic volume (ml) 52 - 34 68 -_27 0.08
End-diastolic volume (m0 125 x 34 153 ± 47 0.04
Ejection fraction (%) 59 s 21 55 ± I t 0.44
Potent infarct-related artery 14 (88%) 1603%) 0.05
Regional watt motion
score
2.9 x 3.7 5
.1 z 3 .6 0.07
Isee text)
After
Index
Infarction
In
= 3311
After
Reinfaretion
(n = 301
P
Value
E daystotic volume (ml) 65 x 33 68 ! 27 0.56
Endaiastdic volume (ml) 147 _ 47 153 47 0.50
Ejection fraction
(%I 57
7
D 55 x 11 0.49
LVEDP Imm Hg)
15 s 7 16'- 5 0.45
Pam.[ infarct-relaled
artery'
255 (76%) 16 (53%) 0.01
Regional wall motion score
We test)
3.8 5 3 .1 5 .1 ± 3.6 0.04
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Figure 3. Changes in left ventricular volume and ejection fraction in
seven patients who underwent ventriculography before and after
reinfarction . Patients whose second infarct occurred in the same
coronary artery territory as the initial infarct are distinguished from
those in whom the second infarct occurred in a different territory.
Angioplasty and surgery . Twenty-five patients (5.5%) un-
derwent coronary artery bypass surgery within 12 months
after infarction, five for left main coronary artery stenosis.
Sixteen patients (3.5%) had angioplasty for management of
severe angina refractory to medical therapy . Two patients
underwent bypass surgery after unsuccessful angioplasty .
No patient developed reinfarction s 12 months after coro-
nary surgery or angioplasty . Two of the surgically treated
patients died in the perioperative period and one patient died
after angioplasty .
Discussion
Intravenous thrombolysis has been shown to significantly
reduce mortality related to acute myocardial infarction in
patients treated s6 h after the onset of pain (1,2) and is
almost certainly beneficial in some patients treated later (2) .
The mechanisms by which this survival benefit is attained
are multiple. The major factor, particularly in those treated
early, appears to be limitation of infarct size with preserva-
tion of left ventricular function (3),
which is the major
predictor of long-term survival after infarction (19) .
Incidence or reinfarction . The incidence of clinical rein-
farction (fatal or nonfatal) observed in this study was rela-
tively low (4 .8% at 30 days and 8 .6% at I year) despite a
conservative management strategy in which recurrent angina
was manage.( medically except for patients with left main
coronary stenosis and those with symptoms refractory to
medical therapy . In the TIMI Phase 11 trial
(12),
which
compared an "invasive" (early investigation and angio-
plasty) with a "conservative" strategy, 5
.8% of patients in
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the conservative group had fatal or nonfatal reinfarction
within 42 days compared with 6.4% in the invasive group. In
the current study, 5 .3% of conservatively treated patients
had fatal or nonfatal reinfarction during this period . At 12
months the nonfatal reinfarction rates in TIMI-11 were 7.5%
in both invasive and conservative groups (20)
. whereas our
nonfatal reinfarction rate was 7.0%. Only 4 .2% of our
patients underwent angioplasty or coronary surgery during
the first 42 days compared with 25.3% of patients receiving
conservative treatment and 65 .6% of those receiving inva-
sive treatment in the TIMI-II trial .
Variables predictive of reinfarction. Considerable atten-
tion has been given to possible predictors of reocclusion
after thrombolysis. Earlier studies (7,21,22) suggested that
the severity of the residual stenosis predicted reocclusion,
which led to the development of clinical strategies including
early angiogmphy and angioplasty after lhrombolysis (8) .
The correlation between severity of the residual lesion or
other morphologic characteristics and reocclusion has since
been questioned
(23), and trials of angioplasty have sug-
gested an overall adverse rather than beneficial effect (9-12).
In our study the majority of the early reinfarctions occurred
before coronary angiography was performed. In the patients
in whom reinfarction occurred after angiography the severity
of the residual stenosis was not predictive of later reinfarc-
tion . None of the 24 patients with 99% cross-sectional area
stenosis had clinical reinfarction and reinfarction was most
common among patients in 75% to 90% stenosis (50% to 70%
diameter), although this trend was not statistically signifi-
cant.
Thrombolytic agent. We observed no difference in the
incidence of reinfarction in patients treated with streptoki-
nase compared with those treated with rt-PA. The pooled
data of clinical trials (Table 6) (1-5,12,16,24-33) suggest that
reinfarction might be more common after rt-PA administra-
tion (3.4% with streptokinase versus 4 .8% with rt-PA, p <
0 .001) . The lack of large direct randomized comparisons,
variability in post-thrombolytic antiplatelet and anticoagu-
lant therapy and variable reliability rf documentation may
well explain the apparent difference .
Exercise testing. As with coronary arteriography, the
potential predictive value of exercise test results applies
only
to events after the test
. Even if exercise stress testing had
been routinely performed at 7 days after infarction, 35% of
reinfarction would have already occurred . The unreliability
of the exercise test in predicting subsequent reinfarction is
concordant with our previous observations in patients who
did not receive thrombolytic therapy
(34) .
Smoking
. Cigarette smoking was the only factor we were
able to identify that was predictive of clinical reinfarction . In
addition. patients who stopped smoking after the index
infarction sustained fewer late reinfarctions than did those
who continued to smoke. Our previous study of long-term
prognosis after myocardial infarction found continued ciga
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Table 6 . Incidence of Rinfarction After Intravenous Streptokinase or rt-PA in Previous Studies
rette smoking to be the only independent factor other than
left ventricular end-systolic volume to influence subsequent
survival (19) .
Cigarette smoking has been shown to be
associated with an increased risk of myocardial infarction
(35)
even in patients with coronary artery disease of compa-
rable severity
(36,37). In addition to promoting atherogene-
sis, smoking may increase the risk of thrombotic events
through increased platelet aggreg:.tion (38-40), increased
serum fibrinogen (41) and decreased prostacyclin production
(42).
Impact
of reocclusion and reinfarction . Infarct-related
arteries rendered patent by thrombolysis may have residual
severe or unstable lesions that may reocclude . Angiographic
studies
(6) suggest an early reocclusion rate of approxi-
mately 20%, which considerably exceeds the incidence of
reinfarction observed in large clinical trials (Table 6). In
some patients all of the myocardium supplied by an artery
may have been irreversibly damaged by the first infarction,
making further infarction impossible, but this seems unlikely
to be the situation in most patients
. Collateral vessels
(ACC
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; [SAM = Intravenous Streptokinase in Acute Myocardial Infarction ; ISIS = International Study of Infarct
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: PALMS = Plasminogen Activator Italian Multicenter Study : TAM( = Thromholysis and Angioplasty in Acute Myocardial Infarction : TIMI =
Thromhotysis in Myocardial Infarction
: TICO - Thrombolysis in Acute Coronary Occlusion .
develop rapidly after coronary occlusion
(43) and may
protect the myocardium during reocclusion (44) . It is also
possible that a variety o! changes induced by "precondition-
ing ischemia" may protect the myocardium during subse-
quent profound ischemia (45).
Potency of the
infarct-related artery may eonfer some
sarvivat advantages independent of left ventricular function
(13,14) and therefore silent reocclusion without infarction
may be detrimental. However, it seems probable that clinical
reinfarction with further myocardial necrosis is more harm-
ful than silent reocclusion without myocardial damage
.
In this study
rigfarction appeared to be associated with
less myocardial necrosis
than the index infarction, as evi-
denced by the lower peak creatine kinase levels. Reinfarc-
tion did, however, have a detrimental effect on left ventric-
ular function (Fig. 3) . Left ventricular volume increased, and
we (19) have shown this to have as even more important
adverse prognostic effect than decreased ejection fraction .
Also, it is clear that reinfarction can he disastrous for some
patients.
Study
Adjunctive Therapy
Time After hides
Infarction Streptokinase
n-PA Control
GISSI-I (I) Heparinloral antienagu)ants 21% .
antiplatelet agents 14%
During hospital stay 4.1%(238/5 .860)
2
.1%(12415.852)
ISIS-20) Aspirin 2092 : heparin 24%
During hospital stay
2 .11%(23818,490) 2.4% (20V8.0 1,
1515-2 (pilot) (24) Aspirin 5092 : heparin for 48 h Dur;ne hospital stay 3 .9% (161413) 2.9%(61206)
50%
ISAM (25) Aspirin : heparinbd
anticoagulants for 3 weeks
21 days 2 .3% (201859) 1.1% (101882)
White et al . (3) Aspirin ; dipyridamole : heparin
for 48 h
30 days 2 .6% (3/112) 1.9% 01107)
White et al . (161 Aspirin : dipyridamole : heparin
for 48 h
3o days 5 .2%(7035) 5.290 (7435)
ECSG (26) Aspirin-streptokinase group :
heparin bolus
During hospital stay 6.2% (4165)
3.1%(2/64)
Verstmete et al . (27) Heparin bolas Denn8 hospital slay 4.7%(31641 0% (0164)
ECSG (28) Aspirin ; hepariNoral
anticoagulants
14 days 3.9%(141355) 4.1% (151366)
TIMI-I (29)
Heparin for 8-10 days : aspirin[
dipyridamole
During hospital stay 11 .6%(171147) 13.3%(19/143)
TIMI-II (12)
(consorvativel
Aspirin for 42 days; heparin for
5 days
42 days
5.8% (94/1 .626)
Topn1 et al. (30)
Heparin Durine hospital stay 4.0% (31751 4 .5% 12125)
TAMI131) Aspirin
: hsposio for 240 Daring hospital .stay 6 .0% (81134)
NHF (S) Heparin
During hospital stay 8 .2% (6/731 4 .2%,(3)71)
TICO (4)
Aspinp/dipyndamole: heparin
for 48 h
During hospital slay 4 .1% (3174) 7 .0%(5171)
PALMS (32) Heparin for 4 days
During hospital say 2.491(2185) 0% (01861
ASSET (33) Heparin for 24 h
During hospital stay 3 .9% (99/2 .512) 4 .6% (114/2 .4931
Total
3.4% (545116.166)' 4 .8% (25815 .341)•
2
.6% (442/18 .6291
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Early readmfnistration of thrombolysic therapy may have
favorably affected the impact of reinfarction in some pa-
tients. Reinfarction was prevented in four patients and
infarct size was probably reduced in others, although this
finding must be interpreted with caution in view of the small
numbers and lack of randomization .
Mortality. The mortality rate at 12 months in this study
was 9 .0% . However, the mortality rate from 42 days to 12
months was only 3
.2%. This is comparable to the mortality
rates in the conservative limb
of
the TIMI-1I trial of 2
4%
for
the same period (20) and it . the TIMI-1 trial of 6 .6% from 21
days to I year (46),
as well as
in Thrombolysis and Angio-
plasty in Acute Myocardial Infarction (TAMP trial of 3.8%
from hospital discharge to a median of 18 months (47) In all
these trials, angioplasty was used much more aggressively
than in our series.
Conclusions . After thrombolysis with streptokinase or
rt-PA and a conservative treatment strategy, clinical rein-
farction rates were approximately 4 .8% at I month and 8 .6%
at I year. Reinfarction was more common in patients who
smoked cigarettes, particularly those who continued to
smoke after the index infarction . These data provide further
support for vigorous efforts to achieve smoking cessation
after myocardial infarction .
Recurrent infarcts tend to be smaller than initial infarcts
but nevertheless cause significant additional worsening of
left ventricular volume. The impact of reinfarction of left
ventricular function may be mitigated by prompt readminis-
tration of thrrombolytic therapy and in some patients rein-
farction may be prevented
.
The relatively low reinfarction and mortality rates in this
study support a policy of conservative management after
thrombolysis, reserving revascularization procedures for the
small proportion of patients with symptoms refractory to
medical therapy and for those with left main coronary
Stenosis .
We gratefully express our appreciation to Toby Whitlock, MB, ChB for
statistical advice and preparation or the actuarial curves, to Carol Caunterand
Anna Breckon for preparation of the manuscript and to the nurses and
physicians who have helped care for the patients in this study .
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